Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal
Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes therapies—through the planned...
Search results for "global"
Deceptive Symptoms in Diagnostic Gaps: 88% of Pediatric Pneumonia Cases Coincide with Viruses
Diagnosing respiratory infections in infants and toddlers using virus-only testing can leave dangerous diagnostic gaps, frequently missing...
Anchoring the U.S. Supply Chain: GC Green Cross Expands 30-Year Cytiva Partnership to Secure Alyglo Production
GC Green Cross has secured priority access to critical manufacturing consumables to stabilize the production of Alyglo,...
TAVI speeds recovery without opening the chest — but age brings more to weigh
For patients diagnosed with severe aortic stenosis and their families, one question often comes first: “Can it be...
Celltrion Secures South Korean Phase 1 Approval for Tremfya Biosimilar CT-P68
Celltrion announced on July 15 that it has received approval from South Korea’s Ministry of Food and Drug Safety for an...
Fast-Tracking Biosimilars: South Korea to Waive Phase 3 Clinical Trials Under New Guidelines
South Korean regulators have revised requirements to significantly reduce the time and financial burden of biosimilar...
Spinal Fusion Through a 1-Centimeter Lens: How Single-Port Endoscopy Replaces the Large Back Incision
"They say they have to put big screws in my lower back to hold it in place, but I’m so scared I can’t bring myself to...
The Next Level of Joint Care: Why Robot-Assisted Hip Surgery Demands a Higher Class of Surgical Expertise
A man in his 60s, referred to as Mr. A, recently visited a clinic to address chronic knee pain.
Landmark Biotech Deal: Celltrion Acquires Autoimmune Disease Antibody Tech from Catholic University of Korea
A research team led by Kim Wan-wook at the Catholic University of Korea College of Medicine has successfully...
Daewoong Pharmaceutical’s Nabota Hits 1 Trillion Won in Cumulative Sales 12 Years Post-Launch
Daewoong Pharmaceutical announced on the 13th that its flagship botulinum toxin product, Nabota, surpassed 1 trillion...